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background: This real-world study evaluated discontinuation rates of apixaban, warfarin, dabigatran, and rivaroxaban in patients with atrial 
fibrillation (AF).
methods: Retrospective cohort study was conducted using the MarketScan® Earlyview data from 01/2012 to 07/2013. AF Patients >18 years 
(ICD-9 code 427.31 or 472.32) with one year of baseline period were included if they were newly prescribed anticoagulation during the study period. 
Discontinuation was defined as lack of subsequent prescription of the index drug within 30 days after the last supply day of the last prescription. Cox 
proportional hazards model was used to compute age- and gender-adjusted relative risk of discontinuation.
results: Among 24,596 eligible patients, 12,758 (51.9%) were on warfarin, 977 (4.0%) on apixaban, 3,278 (13.3%) on dabigatran and 7,583 
(30.8%) on rivaroxaban. Warfarin (mean age: 71.9±12.5 years) and apixaban (70.2±11.9 years) patients were older (P<0.0001) versus those 
prescribed dabigatran (67.5±12.3 years) or rivaroxaban (67.9±12.4 years). After adjusting for age and gender, patients using apixaban were less 
likely to discontinue (P <0.0001 for all comparisons) versus other anticoagulants (Figure).
conclusion: The risk of discontinuation was lower for apixaban versus other anticoagulants among newly anticoagulated AF patients. These early 
findings with relatively short follow-up should be confirmed in future with larger sample size and longer term follow-up.
